Study # GO42909

Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination with Lenalidomide in Comparison to Rituximab in Combination with Lenalidomide in Patients with Follicular Lymphoma After at Least One Line of Systemic Therapy

Study Status:

Enrolling

Treatment Agent:

Mosunetuzumab (BTCT4465A, RO7030816), Lenalidomide, Rituximab, Tocilizumab

Description

Short Title: Celestimo 

This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination with lenalidomide (R + Len) in participants with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one line of prior systemic therapy.

 

Resources and Links

National Clinical Trial Identified Number: NCT04712097

Information and next steps

Disease:

  • Relapsed or Refractory Follicular Lymphoma

Study Phase:

III

Physician Name:

Department:

Ask a Question